Altium Capital Management LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 13, 2025), Altium Capital Management LLC reported 61 stock positions worth $321.1 million. Its top holding was Adma Biologics (ADMA) at 7.5% of the portfolio, followed by Vera Therapeutics (VERA, 5.7%) and Sarepta Therapeutics (SRPT, 4.8%). Compared with Q3 2024, it opened 19 new positions, sold out of 15, added to 18 and reduced 17. The biggest buy was Establishment Labs (ESTA, shares +133%) and the biggest sale Vera Therapeutics (VERA, shares −37%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001746382
- Portfolio Value
- $321.1M (Q4 2024)
- SEC Filing
- 0001420506-25-000357 ↗ filed Feb 13, 2025
Holdings Value
Holdings 61 stocks · $321.1M
| ADMA Adma Biologics Inc. | 7.45% | 1,395,000 | $23.9M | Add +2.6% |
| VERA Vera Therapeutics Inc. | 5.69% | 432,000 | $18.3M | Reduce -36.8% |
| SRPT Sarepta Therapeutics Inc. | 4.81% | 127,000 | $15.4M | Reduce -25.3% |
| ZVRA Zevra Therapeutics Inc. | 4.80% | 1,850,000 | $15.4M | Add +8.8% |
| ESTA Establishment Labs Holdings | 4.38% | 305,000 | $14.1M | Add +132.8% |
| EW Edwards Lifesciences Corp. | 3.80% | 165,000 | $12.2M | Reduce -25.7% |
| XENE Xenon Pharmaceuticals Inc. | 3.52% | 288,000 | $11.3M | Reduce -20.1% |
| SLNO Soleno Therapeutics Inc. | 3.50% | 250,000 | $11.2M | Add +17.4% |
| CAPR Capricor Therapeutics Inc. | 3.07% | 714,000 | $9.9M | Add +150.5% |
| RXST Rxsight Inc. | 3.05% | 285,000 | $9.8M | Add +154.5% |
| MMSI Merit Medical Systems Inc. | 3.01% | 100,000 | $9.7M | Add +17.6% |
| BHVN Biohaven Ltd. | 2.91% | 250,000 | $9.3M | Add +233.3% |
| INSM Insmed Inc. | 2.84% | 132,000 | $9.1M | Add +1.5% |
| RZLT Rezolute Inc. | 2.58% | 1,694,000 | $8.3M | Reduce -0.3% |
| EOLS Evolus Inc. | 2.36% | 685,000 | $7.6M | Add +93.0% |
| ITCI Intra-Cellular Therapies Inc. | 1.95% | 75,000 | $6.3M | Reduce -51.3% |
| ARGX Argenx SE - ADR | 1.92% | 10,000 | $6.2M | New |
| GKOS Glaukos Corp. | 1.87% | 40,000 | $6.0M | Reduce -48.0% |
| RMD Resmed Inc. | 1.85% | 26,000 | $5.9M | New |
| VKTX Viking Therapeutics Inc. | 1.83% | 146,000 | $5.9M | Add +15.9% |
| EXAS Exact Sciences Corp. | 1.75% | 100,000 | $5.6M | New |
| LUNG Pulmonx Corp. | 1.72% | 815,000 | $5.5M | Add +63.0% |
| CMPS Compass Pathways PLC | 1.68% | 1,424,400 | $5.4M | New |
| CPRX Catalyst Pharmaceuticals Inc. | 1.66% | 255,000 | $5.3M | Reduce -33.8% |
| CTNM Contineum Therapeutics Inc. Class A | 1.52% | 334,000 | $4.9M | Reduce -9.5% |
| SNDX Syndax Pharmaceuticals Inc. | 1.52% | 370,000 | $4.9M | New |
| SVRA Savara Inc. | 1.51% | 1,579,000 | $4.8M | Add +0.3% |
| AVDL Avadel Pharmaceuticals Ltd. | 1.48% | 452,475 | $4.8M | Reduce -25.8% |
| CRBP Corbus Pharmaceuticals Holdi | 1.41% | 385,000 | $4.5M | Add +97.4% |
| ARWR Arrowhead Pharmaceuticals Inc. | 1.35% | 230,257 | $4.3M | Reduce -35.1% |
| AVR Anteris Technologies Global | 1.28% | 737,000 | $4.1M | New |
| PROF Profound Medical Corp. | 1.13% | 485,000 | $3.6M | New |
| XTNT Xtant Medical Holdings Inc. | 1.02% | 7,415,413 | $3.3M | No change |
| SKYE Skye Bioscience Inc. | 1.00% | 1,139,000 | $3.2M | Reduce -13.4% |
| ORIC Oric Pharmaceuticals Inc. | 0.89% | 355,000 | $2.9M | No change |
| TGTX TG Therapeutics Inc. | 0.89% | 95,000 | $2.9M | New |
| NKTR Nektar Therapeutics | 0.87% | 3,000,000 | $2.8M | Add +26172.0% |
| KROS Keros Therapeutics Inc. | 0.86% | 175,000 | $2.8M | Add +153.6% |
| IBRX Immunitybio Inc. | 0.85% | 1,060,000 | $2.7M | New |
| LXEO Lexeo Therapeutics Inc. | 0.83% | 405,000 | $2.7M | New |
| TERN Terns Pharmaceuticals Inc. | 0.82% | 475,000 | $2.6M | Add +43.9% |
| RVMD Revolution Medicines Inc. | 0.82% | 60,000 | $2.6M | New |
| EPIX Essa Pharma Inc. | 0.80% | 1,428,000 | $2.6M | New |
| ATEC Alphatec Holdings Inc. | 0.76% | 264,562 | $2.4M | New |
| LRMR Larimar Therapeutics Inc. | 0.61% | 505,000 | $2.0M | Reduce -27.1% |
| OKUR Onkure Therapeutics Inc. Class A | 0.58% | 218,386 | $1.9M | New |
| ACOG Alpha Cognition Inc. | 0.50% | 275,000 | $1.6M | New |
| PRQR Proqr Therapeutics NV | 0.47% | 575,000 | $1.5M | New |
| VERU Veru Inc. | 0.41% | 2,028,534 | $1.3M | No change |
| UNICYCIVE THERAPEUTICS INC | 0.36% | 1,473,000 | $1.2M | No change |
| NVNO Envveno Medical Corporation | 0.29% | 310,000 | $936K | Add +29.8% |
| BCYC Bicycle Therapeutics PLC-ADR | 0.18% | 40,352 | $565K | Reduce -52.5% |
| PMN Promis Neurosciences Inc. | 0.17% | 581,395 | $551K | No change |
| FULC Fulcrum Therapeutics Inc. | 0.16% | 111,812 | $526K | New |
| KPTI Karyopharm Therapeutics Inc. | 0.16% | 740,000 | $500K | No change |
| CTMX Cytomx Therapeutics Inc. | 0.15% | 467,491 | $482K | Reduce -48.9% |
| CATX Perspective Therapeutics Inc. | 0.09% | 92,224 | $294K | Reduce -68.2% |
| SRXH SRX Global Inc. filed as BETTER CHOICE CO INC | 0.09% | 118,459 | $278K | Reduce -11.0% |
| ANAB Anaptysbio Inc. | 0.08% | 18,326 | $243K | New |
| QUOIN PHARMACEUTICALS LTD | 0.06% | 282,249 | $184K | New |
| CLRB Cellectar Biosciences Inc. | 0.02% | 215,000 | $64K | No change |
Options reported separately and not counted above: ESTA calls ($13.8M), SRRK calls ($13.0M), ANAB puts ($2.7M), LRMR calls ($1.5M), XENE calls ($368K), APLT puts ($48K).
Portfolio Sells Q3 2024 → Q4 2024
| VERA Vera Therapeutics Inc. | Reduce -36.8% | 5.69% | −3.34 |
| PCVX Vaxcyte Inc. | Sold out | 0.00% | −2.46 |
| IRTC Irhythm Holdings Inc. | Sold out | 0.00% | −1.91 |
| AXSM Axsome Therapeutics Inc. | Sold out | 0.00% | −1.56 |
| SRPT Sarepta Therapeutics Inc. | Reduce -25.3% | 4.81% | −1.53 |
| ITCI Intra-Cellular Therapies Inc. | Reduce -51.3% | 1.95% | −1.41 |
| REAL The Realreal Inc. | Sold out | 0.00% | −1.19 |
| GKOS Glaukos Corp. | Reduce -48.0% | 1.87% | −1.13 |
| CATX Perspective Therapeutics Inc. | Reduce -68.2% | 0.09% | −1.06 |
| GPCR Structure Therapeutics Inc. | Sold out | 0.00% | −0.92 |
| AVDL Avadel Pharmaceuticals Ltd. | Reduce -25.8% | 1.48% | −0.91 |
| OTLK Outlook Therapeutics Inc. | Sold out | 0.00% | −0.86 |
| VCEL Vericel Corp. | Sold out | 0.00% | −0.86 |
| HELP Cybin Inc. | Sold out | 0.00% | −0.84 |
| LRMR Larimar Therapeutics Inc. | Reduce -27.1% | 0.61% | −0.75 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -20.1% | 3.52% | −0.72 |
| ARWR Arrowhead Pharmaceuticals Inc. | Reduce -35.1% | 1.35% | −0.71 |
| OCGN Ocugen Inc. | Sold out | 0.00% | −0.70 |
| CPRX Catalyst Pharmaceuticals Inc. | Reduce -33.8% | 1.66% | −0.63 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −0.60 |
| CTNM Contineum Therapeutics Inc. Class A | Reduce -9.5% | 1.52% | −0.59 |
| EW Edwards Lifesciences Corp. | Reduce -25.7% | 3.80% | −0.57 |
| SKYE Skye Bioscience Inc. | Reduce -13.4% | 1.00% | −0.53 |
| ATRC Atricure Inc. | Sold out | 0.00% | −0.45 |
| BCYC Bicycle Therapeutics PLC-ADR | Reduce -52.5% | 0.18% | −0.40 |
| TPST Tempest Therapeutics Inc. | Sold out | 0.00% | −0.23 |
| MIST Milestone Pharmaceuticals Inc. | Sold out | 0.00% | −0.20 |
| CTMX Cytomx Therapeutics Inc. | Reduce -48.9% | 0.15% | −0.17 |
| EXPION360 INC | Sold out | 0.00% | −0.03 |
| SCPX Scorpius Holdings Inc. | Sold out | 0.00% | −0.02 |
| SRXH SRX Global Inc. | Reduce -11.0% | 0.09% | +0.00 |
| RZLT Rezolute Inc. | Reduce -0.3% | 2.58% | +0.12 |
Portfolio Buys Q3 2024 → Q4 2024
| ESTA Establishment Labs Holdings | Add +132.8% | 4.38% | +2.68 |
| ARGX Argenx SE - ADR | New | 1.92% | +1.92 |
| RMD Resmed Inc. | New | 1.85% | +1.85 |
| BHVN Biohaven Ltd. | Add +233.3% | 2.91% | +1.79 |
| CAPR Capricor Therapeutics Inc. | Add +150.5% | 3.07% | +1.77 |
| EXAS Exact Sciences Corp. | New | 1.75% | +1.75 |
| CMPS Compass Pathways PLC | New | 1.68% | +1.68 |
| SNDX Syndax Pharmaceuticals Inc. | New | 1.52% | +1.52 |
| RXST Rxsight Inc. | Add +154.5% | 3.05% | +1.40 |
| ZVRA Zevra Therapeutics Inc. | Add +8.8% | 4.80% | +1.28 |
| AVR Anteris Technologies Global | New | 1.28% | +1.28 |
| PROF Profound Medical Corp. | New | 1.13% | +1.13 |
| TGTX TG Therapeutics Inc. | New | 0.89% | +0.89 |
| NKTR Nektar Therapeutics | Add +26172.0% | 0.87% | +0.86 |
| IBRX Immunitybio Inc. | New | 0.85% | +0.85 |
| LXEO Lexeo Therapeutics Inc. | New | 0.83% | +0.83 |
| RVMD Revolution Medicines Inc. | New | 0.82% | +0.82 |
| EPIX Essa Pharma Inc. | New | 0.80% | +0.80 |
| ATEC Alphatec Holdings Inc. | New | 0.76% | +0.76 |
| EOLS Evolus Inc. | Add +93.0% | 2.36% | +0.64 |
| OKUR Onkure Therapeutics Inc. Class A | New | 0.58% | +0.58 |
| ACOG Alpha Cognition Inc. | New | 0.50% | +0.50 |
| MMSI Merit Medical Systems Inc. | Add +17.6% | 3.01% | +0.50 |
| LUNG Pulmonx Corp. | Add +63.0% | 1.72% | +0.49 |
| PRQR Proqr Therapeutics NV | New | 0.47% | +0.47 |
| SLNO Soleno Therapeutics Inc. | Add +17.4% | 3.50% | +0.29 |
| CRBP Corbus Pharmaceuticals Holdi | Add +97.4% | 1.41% | +0.21 |
| FULC Fulcrum Therapeutics Inc. | New | 0.16% | +0.16 |
| ANAB Anaptysbio Inc. | New | 0.08% | +0.08 |
| QUOIN PHARMACEUTICALS LTD | New | 0.06% | +0.06 |
| NVNO Envveno Medical Corporation | Add +29.8% | 0.29% | +0.05 |
| INSM Insmed Inc. | Add +1.5% | 2.84% | +0.00 |
| TERN Terns Pharmaceuticals Inc. | Add +43.9% | 0.82% | −0.00 |
| KROS Keros Therapeutics Inc. | Add +153.6% | 0.86% | −0.33 |
| SVRA Savara Inc. | Add +0.3% | 1.51% | −0.48 |
| VKTX Viking Therapeutics Inc. | Add +15.9% | 1.83% | −0.55 |
| ADMA Adma Biologics Inc. | Add +2.6% | 7.45% | −0.67 |
Options Activity Q3 2024 → Q4 2024
| ESTA Establishment Labs Holdings | call | New | 300,000 | $13.8M |
| SRRK Scholar Rock Holding Corp. | call | New | 300,000 | $13.0M |
| ANAB Anaptysbio Inc. | put | New | 206,200 | $2.7M |
| ANVS Annovis Bio | put | Sold out | 236,400 | $1.9Mbefore exit |
| LRMR Larimar Therapeutics Inc. | call | Add +102.0% | 396,000 | $1.5M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q3 2024 → Q4 2024
| FATBW Fat Brands Inc. -CW25 | *W EXP 07/16/202 | Sold out | 200,000 | $499Kbefore exit |
| NXGLW Nexgel Inc. -CW26 | *W EXP 12/27/202 | Sold out | 225,000 | $91Kbefore exit |
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | Sold out | 731,561 | $51Kbefore exit |
| ONFOW Onfolio Holdings Inc. -27 | *W EXP 01/02/202 | Sold out | 200,000 | $34Kbefore exit |
| WLDSW Wearable Devices Ltd. - 27 | *W EXP 09/14/202 | Sold out | 1,411,600 | $28Kbefore exit |
| MOBXW Chavrant Capital Acq -CW23 | *W EXP 12/21/202 | Sold out | 150,000 | $22Kbefore exit |
| CINGW Cingulate -CW23 | *W EXP 12/10/202 | Sold out | 270,000 | $19Kbefore exit |
| NXLIW Nexalin Technology Inc.- 27 | *W EXP 99/99/999 | Sold out | 105,000 | $8Kbefore exit |
| BNCWW Cea Industries Inc. -CW27 | *W EXP 02/11/202 | Sold out | 250,000 | $6Kbefore exit |
| VSEEW Digital Health Acquist-CW23 | *W EXP 99/99/999 | Sold out | 150,000 | $6Kbefore exit |
| BTMWQ Bitcoin Depot Inc.-CW23 | *W EXP 06/30/202 | Sold out | 50,000 | $2Kbefore exit |
| NEXRW Jeffs Brands Ltd. -27 | *W EXP 08/26/202 | Sold out | 68,681 | $2Kbefore exit |
| NLSPW NLS Pharmaceutics Ltd. -CW25 | *W EXP 02/02/202 | Sold out | 200,000 | $2Kbefore exit |
| CYCUW Cycurion Inc.-CW27 | *W EXP 02/13/203 | Sold out | 100,000 | $2Kbefore exit |
| CDTTW Murphy Canyon Acq-CW27 | *W EXP 09/22/202 | Sold out | 100,000 | $2Kbefore exit |
| MITAW Coliseum Acquisition A -CW28 | *W EXP 08/22/202 | Sold out | 28,333 | $1Kbefore exit |
| SRZNW Surrozen Inc.-CW25 | *W EXP 08/01/203 | Sold out | 82,233 | $1Kbefore exit |
| TCBWF TC Biopharm Holdings Ltd. | *W EXP 02/10/202 | Sold out | 18,823 | $343before exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 19 | $47.5M | RMT, ASA, RVT, NBXG, PDX |
| Q1 2026 | 19 | $42.0M | PDX, ASA, RVT, XPCQX, GAM |
| Q4 2025 | 18 | $25.3M | ASA, RVT, PDX, NBXG, XPCQX |
| Q3 2025 | 1 | $628K | CNSY |
| Q2 2025 | 0 | $0 | |
| Q1 2025Amended | 22 | $34.4M | ZVRA, EOLS, XTNT, AVDL, CTNM |
| Q4 2024 | 61 | $321.1M | ADMA, VERA, SRPT, ZVRA, ESTA |
| Q3 2024 | 57 | $334.9M | VERA, ADMA, SRPT, EW, XENE |
| Q2 2024 | 45 | $241.2M | VERA, ADMA, XENE, ITCI, SRPT |
| Q1 2024 | 46 | $222.3M | VERA, XENE, AXSM, ADMA, ALIM |